-
1
-
-
0032487923
-
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
-
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
-
(1998)
N Engl J Med
, vol.339
, pp. 1341-1348
-
-
Soignet, S.L.1
Maslak, P.2
Wang, Z.G.3
Jhanwar, S.4
Calleja, E.5
Dardashti, L.J.6
-
2
-
-
42449128875
-
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
-
Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19: 379-390.
-
(2008)
Cancer Causes Control
, vol.19
, pp. 379-390
-
-
Yamamoto, J.F.1
Goodman, M.T.2
-
3
-
-
61949441174
-
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
-
(2009)
Blood
, vol.113
, pp. 1875-1891
-
-
Sanz, M.A.1
Grimwade, D.2
Tallman, M.S.3
Lowenberg, B.4
Fenaux, P.5
Estey, E.H.6
-
4
-
-
10744220024
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA Group
-
Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood 2004; 103: 1237-1243.
-
(2004)
Blood
, vol.103
, pp. 1237-1243
-
-
Sanz, M.A.1
Martin, G.2
Gonzalez, M.3
Leon, A.4
Rayon, C.5
Rivas, C.6
-
5
-
-
0033566639
-
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group
-
Fenauz P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 1999; 94: 1192-1200.
-
(1999)
Blood
, vol.94
, pp. 1192-1200
-
-
Fenauz, P.1
Chastang, C.2
Chevret, S.3
Sanz, M.4
Dombret, H.5
Archimbaud, E.6
-
6
-
-
77958499078
-
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by riskadapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group
-
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by riskadapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group. Blood 2010; 116: 3171-3179.
-
(2010)
Blood
, vol.116
, pp. 3171-3179
-
-
Lo-Coco, F.1
Avvisati, G.2
Vignetti, M.3
Thiede, C.4
Orlando, S.M.5
Iacobelli, S.6
-
7
-
-
0037115195
-
All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
-
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
-
(2002)
Blood
, vol.100
, pp. 4298-4302
-
-
Tallman, M.S.1
Andersen, J.W.2
Schiffer, C.A.3
Appelbaum, F.R.4
Feusner, J.H.5
Woods, W.G.6
-
8
-
-
84879409297
-
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients
-
Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 2013; 88: 556-559.
-
(2013)
Am J Hematol
, vol.88
, pp. 556-559
-
-
Adès, L.1
Chevret, S.2
Raffoux, E.3
Guerci-Bresler, A.4
Pigneux, A.5
Vey, N.6
-
9
-
-
0034663162
-
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
-
Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
-
(2000)
Blood
, vol.96
, pp. 1247-1253
-
-
Sanz, M.A.1
Lo Coco, F.2
Martín, G.3
Avvisati, G.4
Rayon, C.5
Barbui, T.6
-
10
-
-
0030610687
-
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
-
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qui QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
-
(1997)
Blood
, vol.89
, pp. 3354-3360
-
-
Shen, Z.X.1
Chen, G.Q.2
Ni, J.H.3
Li, X.S.4
Xiong, S.M.5
Qui, Q.Y.6
-
11
-
-
84880287051
-
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
-
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobellui S et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369: 111-121.
-
(2013)
N Engl J Med
, vol.369
, pp. 111-121
-
-
Lo-Coco, F.1
Avvisati, G.2
Vignetti, M.3
Thiede, C.4
Orlando, S.M.5
Iacobellui, S.6
-
12
-
-
0032417947
-
Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission
-
Ottaviani E, Martinelli G, Testoni N, Visani G, Tani M, Tura S. Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission. Haematologica 1998; 83: 1051-1055.
-
(1998)
Haematologica
, vol.83
, pp. 1051-1055
-
-
Ottaviani, E.1
Martinelli, G.2
Testoni, N.3
Visani, G.4
Tani, M.5
Tura, S.6
-
13
-
-
0027954036
-
European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT)
-
Mandelli F, Labopin M, Granena A, Irionda A, Prentice G, Bacigalupo A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994; 14: 293-298.
-
(1994)
Bone Marrow Transplant
, vol.14
, pp. 293-298
-
-
Mandelli, F.1
Labopin, M.2
Granena, A.3
Irionda, A.4
Prentice, G.5
Bacigalupo, A.6
-
14
-
-
16644373167
-
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group
-
de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120-126.
-
(2005)
J Clin Oncol
, vol.23
, pp. 120-126
-
-
De Botton, S.1
Fawaz, A.2
Chevret, S.3
Dombret, H.4
Thomas, X.5
Sanz, M.6
-
15
-
-
70349583839
-
Auto-SCT for AML in second remission: CALGB study 9620
-
Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009; 44: 353-359.
-
(2009)
Bone Marrow Transplant
, vol.44
, pp. 353-359
-
-
Linker, C.A.1
Owzar, K.2
Powell, B.3
Hurd, D.4
Damon, L.E.5
Archer, L.E.6
-
16
-
-
60049099401
-
Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide
-
Ueki T, Ohashi K, Jinta M, Okuyama Y, Hiruma K, Akiyama H et al. Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide. Pathol Oncol Res 2008; 14: 387-390.
-
(2008)
Pathol Oncol Res
, vol.14
, pp. 387-390
-
-
Ueki, T.1
Ohashi, K.2
Jinta, M.3
Okuyama, Y.4
Hiruma, K.5
Akiyama, H.6
-
17
-
-
84879164951
-
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
-
Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013; 121: 3095-3102.
-
(2013)
Blood
, vol.121
, pp. 3095-3102
-
-
Yanada, M.1
Tsuzuki, M.2
Fujita, H.3
Fujimaki, K.4
Fujisawa, S.5
Sunami, K.6
-
18
-
-
0010740572
-
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
-
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
-
(1996)
Blood
, vol.88
, pp. 1052-1061
-
-
Chen, G.Q.1
Zhu, J.2
Shi, X.G.3
Ni, J.H.4
Zhong, H.J.5
Si, G.Y.6
-
19
-
-
3242666928
-
The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future
-
Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004; 28: 891-900.
-
(2004)
Leuk Res
, vol.28
, pp. 891-900
-
-
Evens, A.M.1
Tallman, M.S.2
Gartenhaus, R.B.3
-
20
-
-
0033568238
-
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
-
Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
-
(1999)
Blood
, vol.94
, pp. 2102-2111
-
-
Jing, Y.1
Dai, J.2
Chalmers-Redman, R.M.3
Tatton, W.G.4
Waxman, S.5
-
21
-
-
0036690367
-
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
-
Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 851-860
-
-
Hayashi, T.1
Hideshima, T.2
Akiyama, M.3
Richardson, P.4
Schlossman, R.L.5
Chauhan, D.6
-
22
-
-
0034663032
-
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
-
Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
-
(2000)
Blood
, vol.96
, pp. 1525-1530
-
-
Roboz, G.J.1
Dias, S.2
Lam, G.3
Lane, W.J.4
Soignet, S.L.5
Warrell, R.P.6
|